Form 4: Celcuity Inc. Director Richard Nigon Acquires Shares and Warrants
SEC Form 4 Filing
Director Richard Nigon reports acquisition of Celcuity Inc. common stock and warrants, along with disposal of common stock, as per Form 4 filing.
Summary
- Richard Nigon, a director of Celcuity Inc., filed a Form 4 detailing changes in beneficial ownership.
- On June 10, 2024, Nigon acquired 5,061 shares of common stock at a price of $9.50 per share.
- On June 10, 2024, Nigon disposed of 101,093 shares of common stock.
- Nigon also acquired warrants to purchase 5,061 shares of common stock at $9.50, expiring on September 22, 2024.
- The filing also lists various warrants and stock options held by Nigon with different exercise prices and expiration dates.
Sentiment
Score: 5
Explanation: The sentiment is neutral. The director acquired some shares, which could be seen as positive, but also disposed of a larger amount of shares, which could be seen as negative. The filing primarily reflects routine transactions related to stock options and warrants.
Positives
- The acquisition of shares by a director could be interpreted as a sign of confidence in the company's future prospects.
Negatives
- The disposal of 101,093 shares of common stock by a director could be interpreted as a sign of lack of confidence in the company's future prospects.
Risks
- The Form 4 filing itself doesn't inherently present risks, but the transactions disclosed could reflect the director's assessment of the company's prospects, which may or may not align with other investors' views.
- The warrants have various expiration dates, and their value depends on the future stock price of Celcuity Inc.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The market often interprets these filings as signals of management's confidence (or lack thereof) in the company's prospects.
Comparison to Industry Standards
- Comparing insider transactions to those of peers in the biotechnology sector can provide context.
- For example, similar filings from directors at companies like Amgen (AMGN) or Gilead Sciences (GILD) are closely watched by investors.
- However, direct comparisons are difficult without knowing the specific circumstances of each transaction (e.g., stock option grants, open market purchases, etc.).
Stakeholder Impact
- Shareholders may react to the reported transactions, potentially influencing the stock price.
- Employees holding stock options or warrants may be interested in the exercise prices and expiration dates.
Key Dates
| Date | Description |
|---|---|
| 06/10/2024 | Date of common stock and warrant transaction |
| 09/22/2024 | Expiration date of warrants acquired on 06/10/2024 |
| 01/14/2026 | Expiration date of warrants |
| 05/02/2026 | Expiration date of warrants |
| 04/28/2027 | Expiration date of warrants |
| 05/17/2027 | Expiration date of warrants |
| 10/19/2027 | Expiration date of stock options |
| 05/14/2028 | Expiration date of stock options |
| 05/16/2029 | Expiration date of stock options |
| 05/14/2030 | Expiration date of stock options |
| 05/12/2031 | Expiration date of stock options |
| 05/17/2032 | Expiration date of stock options |
| 05/15/2033 | Expiration date of stock options |
| 06/04/2034 | Expiration date of stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.